UPCOMING DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, April 16, 2021 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a…

LOS ANGELES, April 16, 2021 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Athenex, Inc. («Athenex» or «the Company») (NASDAQ: ATNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between August 7, 2019 and February 26, 2021, inclusive (the »Class Period»), are encouraged to contact the firm before May 3, 2021.    

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Athenex announced on March 1, 2021, that the FDA had issued a complete response letter («CRL») for the company’s New Drug Application («NDA») for oral paclitaxel plus encequidar for the treatment of metastatic breast cancer. The FDA’s CRL cited patient safety risks and uncertainty related to primary endpoint results for the objective response rate («ORR») which may have introduced bias in the blinded clinical review. The FDA recommended the Company «conduct a new adequate and well-conducted clinical trial in a patient population with metastatic breast cancer representative of the population in the U.S.» The FDA also indicated that the toxicity would require a risk mitigation strategy for the treatment to be approved. Based on this news, shares of Athenex fell by 55% in one day.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com 

Office: 310-301-3335

info@schallfirm.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/upcoming-deadline-reminder-the-schall-law-firm-reminds-investors-of-a-class-action-lawsuit-against-athenex-inc-and-encourages-investors-with-losses-in-excess-of-100-000-to-contact-the-firm-301270701.html

SOURCE The Schall Law Firm